CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V, Pimanda JE, Maitland NJ, Westermarck J, Visakorpi T.
Khanna A, et al. Among authors: manni v.
Oncotarget. 2015 Aug 14;6(23):19661-70. doi: 10.18632/oncotarget.3875.
Oncotarget. 2015.
PMID: 25965834
Free PMC article.